SZC010 suppresses breast cancer development by regulating the PI3K/Akt/NF-κB signaling pathway
Chinese Clinical Oncology · 2024
DOI: 10.21037/cco-24-10 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chinese Clinical Oncology, 2024. Verfasst von Junhan Jiang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, the First Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Proto-Oncogene Proteins c-akt, Signal Transduction, NF-kappa B. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, the First Hospital of China Medical University, Shenyang, China.
- Department of Breast Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, Shenyang, China.
- ICU Department, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, Shenyang, China.
- Department of Breast Surgery, the First Hospital of China Medical University, Shenyang, China; Lab 1, Cancer Institute, the First Hospital of China Medical University, Shenyang, China.
Zitieren
APA
Jiang, J., Li, X., Xu, H., Ma, Y., Fu, M., Guo, X., Sun, T., & Zheng, X. (2024). SZC010 suppresses breast cancer development by regulating the PI3K/Akt/NF-κB signaling pathway. Chinese Clinical Oncology. https://doi.org/10.21037/cco-24-10
Vancouver
Jiang J, Li X, Xu H, Ma Y, Fu M, Guo X, et al. SZC010 suppresses breast cancer development by regulating the PI3K/Akt/NF-κB signaling pathway. Chinese Clinical Oncology. 2024. doi:10.21037/cco-24-10
BibTeX
@article{Jiang2024,
author = {Jiang, Junhan and Li, Xiaorui and Xu, Hongtao and Ma, Yiwen and Fu, Meiyi and Guo, Xiangyu and Sun, Tao and Zheng, Xinyu},
title = {SZC010 suppresses breast cancer development by regulating the PI3K/Akt/NF-κB signaling pathway},
journal = {Chinese Clinical Oncology},
year = {2024},
doi = {10.21037/cco-24-10}
}
EUVIMED